Unleashing the power of ATTOBODY® technology to develop new medicines
ATTOBODIES are biparatopic biologics; that is, each ATTOBODY binds to two different epitopes on the target molecule, creating a two-handed hold. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, which drives best-in-class potency in biologic activity. ATTOBODY binder arms are small, with the potential to bind target difficult-to-access epitopes, and their biparatopic binding can functionalize epitopes that individually are biologically inactive. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of bispecifics and multispecifics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development.
Unleashing the power of ATTOBODY® technology to develop new medicines
ATTOBODIES are biparatopic biologics; that is, each ATTOBODY binds to two different epitopes on the target molecule, creating a two-handed hold. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, which drives best-in-class potency in biologic activity. ATTOBODY binder arms are small, with the potential to bind target difficult-to-access epitopes, and their biparatopic binding can functionalize epitopes that individually are biologically inactive. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of bispecifics and multispecifics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development.
ATTOBODY®
ATTOBODIES are composed of two binder arms connected through proprietary spatial positioning technology. This technology orients the arms in an optimal configuration to drive desired target engagement.
Currently, our ATTOBODIES utilize VHHs as their binder arms. The VHH format is a well-understood framework that is clinically and commercially validated, naturally derived, and easily obtained.
ATTOBODIES are a flexible modality that can be used in their native form, as well as easily built out as bi- and multimers, fused to Fc-domains to modulate effector functions or extending half-life, or conjugated to various payloads.
ATTOBODY®
ATTOBODIES are composed of two binder arms connected through proprietary spatial positioning technology. This technology orients the arms in an optimal configuration to drive desired target engagement.
Currently, our ATTOBODIES utilize VHHs as their binder arms. The VHH format is a well-understood framework that is clinically and commercially validated, naturally derived, and easily obtained.
ATTOBODIES are a flexible modality that can be used in their native form, as well as easily built out as bi- and multimers, fused to Fc-domains to modulate effector functions or extending half-life, or conjugated to various payloads.
